Overview
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2018-02-07.
61 1140 2004 0000 3602 7788 0400
83 1950 0001 2006 0052 8576 0002
Debt
No entries in the National Debtors Register (KRZ).
Public aid
9 public aid cases recorded, with a total value of $155,357.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 12, 2026 | Aid for microenterprises in the form of public interventions concerning electricity, gas or heat supplies | $0$0 | Energa - Obrót S.A. | |
| Dec 6, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $11,592$11,592 | Stowarzyszenie Zachodniopomorski Klaster Chemiczny Zielona Chemia | |
| Aug 10, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $11,146$11,146 | HRP Czernecka, Jaszczyński sp. j. |
Public procurement
Medifar is the contractor in one public sector contract, worth USD 188.52.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Jul 29, 2026 | zakup i dostawa leku | $188.52 | Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych I Administracji w Koszalinie |
Trademarks
Medifar holds 9 active trademarks registered with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2016.
| Mark | Protected until | |
|---|---|---|
| Remagel(word) | Apr 28, 2035 | |
| AYUMEDIC(word) | Jan 21, 2035 | |
| Maść Grizzly(word) | Mar 27, 2037 | |
| Altagel(word) | Mar 27, 2037 | |
| Islandica(word) | May 13, 2036 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Each member of the management board represents the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Paweł Boś (43) | 1,552 | $20,961.64 | 48.5% |
Tomasz Jakub Rączka (40) | 1,552 | $20,961.64 | 48.5% |
Others | 96 | $1,296.60 | 3% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
FAQ
Last updated: 2026-04-28